Parray Aijaz, Siddique Hifzur R, Nanda Sanjeev, Konety Badrinath R, Saleem Mohammad
Molecular Chemoprevention and Therapeutics, The Hormel Institute, University of Minnesota, Austin.
Biologics. 2012;6:267-76. doi: 10.2147/BTT.S23954. Epub 2012 Aug 17.
The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is undergoing significant changes with the advent of new therapies and multidisciplinary efforts by scientists and clinicians. As activation of multiple molecular pathways in the neoplastic prostate makes it impossible for single-target drugs to be completely effective in treating CRPC, this has led to combination therapy strategy, where several molecules involved in tumor growth and disease progression are targeted by a therapeutic regimen. In the present review, we provide an update on the molecular pathways that play an important role in the pathogenesis of CRPC and discuss the current wave of new treatments to combat this lethal disease.
随着新疗法的出现以及科学家和临床医生的多学科努力，去势抵抗性前列腺癌（CRPC）患者的治疗格局正在发生重大变化。由于肿瘤性前列腺中多种分子途径的激活使得单靶点药物在治疗CRPC时不可能完全有效，这导致了联合治疗策略，即通过一种治疗方案针对几种参与肿瘤生长和疾病进展的分子。在本综述中，我们提供了在CRPC发病机制中起重要作用的分子途径的最新信息，并讨论了当前对抗这种致命疾病的新一波治疗方法。
